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No association of tobacco use and disease
activity in multiple sclerosis
ABSTRACT
Objective: To study whether tobacco use is associated with MRI and clinical disease activity in
patients with multiple sclerosis (MS).
Methods: Prospective cohort study of 87 patients with relapsing-remitting MS originally included
in a randomized placebo-controlled trial of omega-3 fatty acids in MS (the OFAMS Study). Serum
levels of cotinine (biomarker of tobacco use) were analyzed at baseline and every 6 months for
2 years. MRI activity was assessed at baseline and monthly for 9 months and after 12 and
24 months.
Results: Fifty-three patients (61%) had serum cotinine levels $85 nmol/L on $60% of the meas-
urements and were considered tobacco users and 34 (39%) had cotinine levels ,85 nmol/L,
consistent with non–tobacco use. There was no association between tobacco use and the occur-
rence of new gadolinium-enhancing T1 lesions, new or enlarging T2 lesions, or their aggregate
(combined unique activity). Furthermore, there was no association between cotinine levels and
MRI activity for the tobacco users, and tobacco users did not have more relapses or Expanded
Disability Status Scale progression.
Conclusion: Our results indicate that tobacco use does not directly influence MRI activity or
relapse rate in MS. This may implicate that the reported association between smoking and MS
disease progression could be mediated through other mechanisms. Neurol Neuroimmunol
Neuroinflamm 2016;3:e260; doi: 10.1212/NXI.0000000000000260
GLOSSARY
BMI 5 body mass index; CI 5 confidence interval; EDSS 5 Expanded Disability Status Scale; HLA 5 human leukocyte
antigen; IFN-b-1a 5 interferon beta-1a; MS 5 multiple sclerosis; OR 5 odds ratio; RRMS 5 relapsing-remitting multiple
sclerosis; SPMS 5 secondary progressive multiple sclerosis; T1Gd 5 T1-weighted gadolinium-enhanced.
Multiple sclerosis (MS) is an inflammatory disease of the CNS. The etiology is unknown, but
there seems to be an interaction between genetic and environmental risk factors.1 Several human
leukocyte antigen (HLA) subtypes are known to increase the risk of MS,2 and several environ-
mental factors such as low serum vitamin D levels, Epstein-Barr virus infection, and smoking are
associated with MS.3,4
Smoking is a known risk factor for developing MS.3,5–8 Smokers with clinically isolated
syndrome have been reported to have earlier progression to clinically definitive MS than non-
smokers,9 and smoking has been suggested to decrease the time for disease conversion from
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relapsing-remitting MS (RRMS) to secondary
progressive MS (SPMS).10–14 It has been sug-
gested that smoking influences the clinical
progression in MS and several studies have
explored this, with conflicting results.12,15,16
One study has reported that smoking cessation
decreases the risk of Expanded Disability Sta-
tus Scale (EDSS) progression,14 but a recent
report did not find any association between
tobacco use and MS activity or progression
over a 5-year follow-up.17
To address the effect of tobacco use in es-
tablished MS, we examined the associations
among serum cotinine levels, MRI, and clini-
cal disease activity in a 2-year longitudinal
study of 87 HLA-DRB1*15–typed patients
with RRMS.
METHODS Standard protocol approvals, registrations,
and patient consents. The study was approved by the Regional
Committee for Medical and Health Research Ethics in Western
Norway Regional Health Authority, and all participants gave
written informed consent.
Study participants and design. The study design has been
presented previously.18–20 In brief, this was a cohort study of 87
patients with RRMS according to the McDonald criteria originally
included in a randomized placebo-controlled trial of omega-3 fatty
acids at 13 Norwegian MS centers from December 2004 until July
2008 (the OFAMS [v-3 Fatty Acid Treatment in Multiple
Sclerosis] Study). Included patients had $1 clinical relapse,
a new T1-weighted gadolinium-enhanced MRI (T1Gd)-positive
lesion or enlarging T2 lesions in the last 12 months before
enrollment. The patients were followed for 24 months with
thorough examinations including serum samples, MRI scans, and
clinical scorings. MRI scans were performed at baseline and
monthly for 9 months and then after 12 and 24 months
according to a standardized protocol.18 The sum of T1Gd1
lesions and new or enlarging T2 lesions was denoted as
combined unique activity. Clinical data were recorded by
experienced neurologists, including EDSS scores every 6 months
and clinical relapses throughout the study period. The patients did
not use any immune modulatory drugs at inclusion, but from
month 6, all patients started subcutaneous injections with 44 mg
of interferon beta-1a (IFN-b-1a) (Rebif; Merck KGaA, Darmstadt,
Germany) 3 times weekly. All patients were randomized to receive
omega-3 fatty acids (Triomar; Pronova Biocare AS, Sandefjord,
Norway) or placebo (corn oil) daily throughout the study period.
Since no effects from omega-3 fatty acid supplementation on MS
disease activity were detected in any part of the study, all patients
were pooled in the current analysis.
Measurements. Cotinine is a nicotine metabolite with a half-life
of 15 to 40 hours. It is the most widely used biomarker for recent
tobacco use and has a high sensitivity (96%–97%) and specificity
(99%–100%).21 The serum levels reflect tobacco exposure during
the prior 3 to 5 days. Serum samples were stored at 280°C until
analysis, which was performed simultaneously for all samples
from each patient. The laboratory technicians were blinded for
the clinical and radiologic status of the patients. Serum levels of
cotinine were measured using liquid chromatography tandem
mass spectrometry at Bevital AS (Bergen, Norway). The
method was highly sensitive and specific with a lower limit of
detection at 1 nmol/L. The within-day coefficient of variation was
2.0% to 6.6% and the between-day coefficient of variation was
3.9%. We analyzed serum samples from patients at baseline and
months 6, 12, 18, and 24.
Cotinine levels .85 nmol/L are indicative of recent tobacco
use22 and are regarded as the optimal cutpoint widely used for
distinguishing tobacco users from non–tobacco users in the gen-
eral population.21 Cotinine has the advantage over other tobacco
biomarkers that the optimal cutpoints are little affected by the
prevalence of smoking in the population sampled.23 This is also
the cutoff value recommended by Bevital AS, the laboratory
where the serum analyses were performed.24
The patients were categorized into 2 groups according to
serum cotinine level. Patients with serum cotinine level $85
nmol/L in $60% of the samples were considered tobacco users
and patients with serum cotinine levels,85 nmol/L in$60% of
the samples were considered non–tobacco users.
The HLA-DRB1*15 analyses have been described
previously.18,20,25
Missing values. A total of 9 MRI scans (1 during study months
1–6 and 8 during study months 7–24) were missing. Seven blood
samples for serum cotinine analysis were missing for months 0 to
6 and 39 were missing for months 7 to 24.
Statistics. Data were described as frequencies and percentages or
means and SDs, as appropriate. The differences in number of re-
lapses and baseline EDSS scores among smokers and nonsmokers
were assessed using independent-samples t test.
The association between tobacco use andMRI activity was as-
sessed using a logistic regression model for hierarchical data. The
model contained fixed effect for smoking status and random ef-
fects for intercepts correctly adjusting the estimates for intrapa-
tient correlations. The model was estimated for total study
period as well as for periods before and during IFN-b-1a treat-
ment. All models were also adjusted for sex, age, body mass index
(BMI), and HLA-DRB1*15 status. The association between co-
tinine levels and MRI activity among tobacco users (serum coti-
nine$85 nmol/L) was also assessed by a logistic regression model
for hierarchical data with fixed effect for cotinine level and ran-
dom effects for intercepts.
All tests were 2-sided. Results with p values ,0.05 were
considered statistically significant. The analyses were performed
in SAS version 9.4 (SAS Institute, Cary, NC) and SPSS version
22 (IBM Corp., Armonk, NY).
RESULTS Cotinine levels and MRI disease activity. Of
87 patients, 53 (61%) had cotinine levels.85 nmol/L
in$60% of the samples and were considered tobacco
users, and 34 (39%) were considered non–tobacco
users. Most patients had consistent cotinine levels on
all samples, but 11 (13%) had consistent levels in 75%
of the measurements and 4 (5%) in 60% of the meas-
urements. There was no association between tobacco
use and MRI activity, for new T1Gd1 lesions (odds
ratio [OR] 5 0.76; 95% confidence interval [CI]
0.41–1.43; p5 0.39), for new or enlarging T2 lesions
(OR 5 0.81; 95% CI 0.42–1.56; p 5 0.52), and for
combined unique activity (OR5 0.81; 95% CI 0.43–
1.53; p 5 0.51) for the total study period. The result
was consistent for the 6 months before and 18 months
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during IFN-b-1a treatment. Adjusting for sex, age,
BMI, and HLA-DRB1*15 status did not influence
our results (table). Similarly, when only analyzing
tobacco users by logistic regression model for hierar-
chical data, there was no association between cotinine
levels and MRI activity during the 2-year follow-up
(OR 5 0.98; 95% CI 0.94–1.04; p 5 0.52).
Cotinine levels and clinical disease activity. A total of 42
relapses were recorded in 23 patients, of which 14
occurred during the first 6 study months. There was
no difference in number of relapses between the tobacco
users and non–tobacco users, with a mean number of
relapses of 0.42 (SD5 0.77) for tobacco users and 0.59
(SD 5 1.18) for non–tobacco users (p 5 0.41).
There was no difference in baseline EDSS score
between tobacco users (mean of 1.92, SD 5 0.85)
and non–tobacco users (mean of 1.85, SD 5 0.84)
(p 5 0.7). During the study period, 26 patients pro-
gressed $1 EDSS point. A total of 19 (37%) of the
tobacco users had EDSS progression compared to
7 (21%) of the non–tobacco users, but the difference
was not significant (p 5 0.14).
DISCUSSION In this cohort of patients with MS, we
could not detect any association between tobacco use,
assessed by serum cotinine levels, and MRI or clinical
disease activity.
This study was performed in a well-characterized
cohort of patients with RRMS prospectively fol-
lowed for 2 years with repeated and paired
MRI scans and measurements of cotinine levels
both before and during IFN-b-1a treatment. The
results were adjusted for sex, age, BMI, and HLA-
DRB1*15 status. All MRI, biochemical, and clin-
ical assessments were performed with strict and
standardized procedures.
There are some limitations to our study. We used
serum cotinine levels as a proxy for smoking behavior,
but being a marker for tobacco use, the levels will also
be high among snuff users or users of nicotine gum,
and one study has suggested possible protective effects
of these considering MS risk.26 The total proportion
of smokeless tobacco of all tobacco consumption in
Norway during the study period was, however, less
than 20% and even lower among women.27 It is
therefore reasonable to assume that the cotinine levels
in our samples mainly reflect smoking. The patients
were classified as tobacco users or non–tobacco users
based on cotinine level in $60% of the measure-
ments, and there is a risk of misclassification, possibly
mostly for light smokers since the half-life of serum
cotinine is 15 to 40 hours. However, we had serum
measurements at 5 different time points and most
patients had consistent serum cotinine levels on all
measurements, indicating that this is not a major
issue. It has also been demonstrated that serum coti-
nine levels are well correlated with patient-reported
smoking behavior.28 The follow-up period of
24 months is relatively short and our results might
have been different with longer follow-up. However,
our findings are in coherence with those of a recently
published study with a follow-up period of 5 years.17
Also, the lack of any of the results being even close to
significant toward influence of tobacco use on MRI
disease activity make it unlikely that there is any asso-
ciation. Our MRI findings were supported by no
association between cotinine levels and clinical disease
activity. The follow-up period was short and few re-
lapses were reported, thus the sensitivity for clinical
activity is low. However, our main outcome was MRI
activity, which is a sensitive and well-known assess-
ment for subclinical disease activity.
Table Odds ratios for MRI disease activity associated with tobacco use (serum cotinine ‡85 nmol/L) in patients with relapsing-remitting
multiple sclerosis





Odds ratio (95% CI) p Value Odds ratio (95% CI) p Value Odds ratio (95% CI) p Value
MRI measure
New T1Gd1 lesions 0.76 (0.41–1.43) 0.39 0.80 (0.34–1.87) 0.61 0.56 (0.19–1.63) 0.28
New T2 lesions 0.81 (0.42–1.56) 0.52 0.74 (0.30–1.81) 0.74 0.85 (0.35–2.08) 0.72
CUA 0.81 (0.43–1.53) 0.51 0.75 (0.31–1.82) 0.52 0.80 (0.32–1.98) 0.62
Adjusted for sex, age, BMI, and
HLA-DRB1*15 status (n 5 81)
New T1Gd1 lesions 0.76 (0.39–1.50) 0.43 0.72 (0.28–1.81) 0.47 0.68 (0.21–2.19) 0.51
New T2 lesions 0.87 (0.43–1.75) 0.69 0.65 (0.26–1.68) 0.37 1.04 (0.40–2.72) 0.94
CUA 0.84 (0.42–1.68) 0.63 0.63 (0.25–1.61) 0.33 0.98 (0.37–2.61) 0.97
Abbreviations: BMI 5 body mass index; CI 5 confidence interval; CUA 5 combined unique activity; IFN-b 5 interferon beta; T1Gd 5 T1-weighted
gadolinium-enhanced.
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The lack of any association between smoking and
EDSS progression in our study could be attributable
to the relatively short follow-up time of 24 months,
and the fact that few patients experienced EDSS pro-
gression during the study period. A number of earlier
studies have reported increased risk of disease progres-
sion among smokers.14,15 The mechanism for this
association is largely unknown, but one possibility
could be that smoking increases the inflammatory
activity in MS. It has been demonstrated in the exper-
imental autoimmune encephalitis model of MS that
proinflammatory T cells are activated in the lungs
before they attack the brain.29 Although our negative
results may implicate that this mechanism does not
have a major role in patients with established MS,
they do not exclude this possibility, or that smoking
has an important role during the initiation phase of
the disease. Smoking is one of the most attractive and
studied environmental risk factors for MS. The first
reports on an association between MS and smoking
were published in the 1990s,30,31 and since then,
a number of studies have confirmed smoking as a risk
factor for MS.5–7,26,32 Even passive smoking has been
associated with MS.33 Recent studies have also
described the association between cotinine levels in
serum and the risk of MS.34,35 Previous reports have
found an association with clinical disease and earlier
progression from clinically isolated syndrome to
RRMS and from RRMS to SPMS among smok-
ers.10–13,36 However, others have not been able to
confirm an association between smoking and the risk
of MS or an earlier progression to SPMS in smok-
ers.16,37 Only a few studies have examined how smok-
ing influences disease activity in MS. One study
explored the association between MRI lesions in
MS and smoking and found that the T2-weighted
lesion volume increased faster in smokers,10 and
a recently published study reported no association
between MRI activity and serum cotinine levels.17
The result of our study supports this latter report.
Other hypothesized mechanisms of adverse effects
of smoking in MS include chronic cyanide intoxica-
tion leading to demyelination, the direct effect of
cigarette-smoke components on the blood–brain bar-
rier and smoking-mediated increased frequency and
persistence of infections.11 There are also several other
possible reasons for the increased impairment and
disability in patients with MS who smoke and it is
not clear whether it is a direct effect of tobacco use or
a consequence of comorbidities associated with
smoking.38
Our results do not support a short-term (2 years)
influence of tobacco use on MRI and clinical disease
activity in MS. Long-term effects and the importance
of comorbidities influenced by smoking in MS need
to be explored.
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